My NCBISign In

Display Settings:

Format

Send to:

Choose Destination

    Curr Opin Pharmacol. 2003 Aug;3(4):426-34.

    Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents.

    Ward SG, Finan P.

    Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, UK. S.G.Ward@bath.ac.uk

    The phosphoinositide 3-kinase (PI3K) family of enzymes consists of several closely related isoforms that are thought to have distinct biological roles. Until now, researchers have been frustrated by poor selectivity of the available pharmacological inhibitors, which are unable to distinguish adequately the activities of different PI3K isoforms. Recently published patent specifications describe new PI3K inhibitors, including several that are selective for the PI3Kdelta isoform. There is now cautious optimism that isoform-selective PI3K inhibitors will provide new avenues for therapeutic applications in a range of diseases.

    PMID: 12901953 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read
    Write to the Help Desk